Esperion Q2 revenue jumps 186% to $73.8M; monetizes European royalties for $304.7M

Esperion Therapeutics, Inc.

2024-Q2 EPS reported -$0.01 revenue$211,569,000

Total revenue $73.8M (+186% YoY); U.S. product revenue $28.3M (+39% YoY).
Monetized European royalties to OMERS for $304.7M; used proceeds to pay off Oberland facility and remove liens.
Net loss $61.9M ($0.33 loss per share) vs $49.9M loss in Q2 2023; cash $189.3M.
Retail prescription equivalents increased 11% in final four weeks of Q2; >21,000 prescribers.
Reiterated FY2024 operating expense guidance $225M-$245M; patent extension for bempedoic acid to Dec 2030.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.